FDA approves first anticoagulant for pediatric patients to treat potentially life-threatening blood clotsAnticoagulants, Approvals, Blood Thinner, Boxed Warning, Congenital Heart Disease, FDA, FDA/Regulatory, New Indications, Priority Review Status, Symptomatic Venous Thromboembolism (VTE)The U.S. FDA approved Fragmin (dalteparin sodium) injection, for subcutaneous use, to reduce the recurrence of symptomatic venous thromboembolism in pediatric patients 1 month of age and older. Read more May 16, 2019/by PR Newswire https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png 0 0 PR Newswire https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png PR Newswire2019-05-16 12:31:092019-05-17 13:12:40FDA approves first anticoagulant for pediatric patients to treat potentially life-threatening blood clots
